A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.
The FDA has approved Gazyva (obinutuzumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.
The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research at the American College of Rheumatology (ACR) Convergence 2025 meeting in ...
FDA approval of Gazyva expands therapeutic options for lupus care WASHINGTON, Oct. 20, 2025 /PRNewswire/ -- The U.S. Food and ...
Hydroxychloroquine did not slow progression from incomplete to full-blown systemic lupus erythematosus (SLE) in patients who had antinuclear antibody (ANA) positivity and met one or two SLE ...
It is Hispanic Heritage Month, and NBC 10 is highlighting some of the many cultures being celebrated. Dominican Americans Margaret Brassard and Aida Gomez tag-teamed to host an event at Lunch Box, a ...
Individuals with lupus may be at a higher risk of developing interstitial cystitis, a chronic condition characterized by inflammation, pain, and pressure in the bladder. Interstitial cystitis, also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback